← Back to Search

Monoclonal Antibodies

IOV-4001 for Melanoma and Lung Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Iovance Biotherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be assessed as having at least one resectable lesion.
Participants who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Must not have
Participants who have symptomatic untreated brain metastases.
Participants who have another primary malignancy within the previous 3 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year or depending on when the recommended phase 2 dose is determined
Awards & highlights

Summary

This trial is testing IOV-4001, a modified immune cell treatment, in adults with advanced melanoma or lung cancer. The treatment aims to improve the ability of the patient's own immune cells to attack cancer by disabling a gene that helps cancer hide.

Who is the study for?
Adults with advanced melanoma or non-small-cell lung cancer (NSCLC) that can't be surgically removed. They must have had certain prior treatments, good organ function, and no untreated brain metastases or recent live vaccines. Participants need a measurable lesion for the study and agree to use effective birth control.
What is being tested?
The trial is testing IOV-4001 infusion's effectiveness and safety in treating unresectable/metastatic melanoma or advanced NSCLC. It will involve adults who meet specific health criteria and have received previous therapies relevant to their cancer stage.
What are the potential side effects?
While not explicitly listed here, side effects may include typical reactions to infusions such as pain at the injection site, fever, chills, nausea, fatigue, allergic reactions; organ inflammation due to immune response; increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have at least one tumor that can be surgically removed.
Select...
I am fully active or can carry out light work.
Select...
I have been diagnosed with advanced melanoma or non-small cell lung cancer.
Select...
I have received platinum-based chemotherapy.
Select...
I have at least one tumor that can be measured and was removed for a specific treatment.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have brain metastases that haven't been treated and are causing symptoms.
Select...
I have had another type of cancer in the last 3 years.
Select...
My melanoma originates from the eye.
Select...
I need more than 10 mg/day of prednisone or an equivalent steroid.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year or depending on when the recommended phase 2 dose is determined
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year or depending on when the recommended phase 2 dose is determined for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Phase 2: Objective Response Rate (ORR)
Phase I: Safety of IOV-4001
Secondary study objectives
CR Rate
Disease Control Rate (DCR)
Duration of Response (DOR)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2Experimental Treatment1 Intervention
Participants with Stage III or IV non-small-cell lung cancer
Group II: Cohort 1Experimental Treatment1 Intervention
Participants with unresectable or metastatic melanoma

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for melanoma, particularly cellular therapies and immunotherapies, work by harnessing the body's immune system to target and destroy cancer cells. Cellular therapies, such as tumor-infiltrating lymphocytes (TILs), involve extracting immune cells from the patient, expanding them in the lab, and reinfusing them to attack the melanoma. Immunotherapies, like checkpoint inhibitors (e.g., nivolumab and ipilimumab), block proteins that prevent immune cells from attacking cancer, thereby enhancing the immune response against melanoma cells. These treatments are significant for melanoma patients as they offer targeted approaches that can lead to durable responses and potentially long-term remission, especially in cases where traditional therapies have failed.

Find a Location

Who is running the clinical trial?

Iovance Biotherapeutics, Inc.Lead Sponsor
23 Previous Clinical Trials
1,772 Total Patients Enrolled
Iovance Biotherapeutics Study TeamStudy DirectorIovance Biotherapeutics
4 Previous Clinical Trials
940 Total Patients Enrolled

Media Library

IOV-4001 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05361174 — Phase 1 & 2
Non-Small Cell Lung Cancer Research Study Groups: Cohort 1, Cohort 2
Non-Small Cell Lung Cancer Clinical Trial 2023: IOV-4001 Highlights & Side Effects. Trial Name: NCT05361174 — Phase 1 & 2
IOV-4001 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05361174 — Phase 1 & 2
~11 spots leftby Jun 2025